CA2882437C - Method of adjuvant cancer treatment - Google Patents

Method of adjuvant cancer treatment Download PDF

Info

Publication number
CA2882437C
CA2882437C CA2882437A CA2882437A CA2882437C CA 2882437 C CA2882437 C CA 2882437C CA 2882437 A CA2882437 A CA 2882437A CA 2882437 A CA2882437 A CA 2882437A CA 2882437 C CA2882437 C CA 2882437C
Authority
CA
Canada
Prior art keywords
dabrafenib
trametinib
melanoma
patient
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2882437A
Other languages
English (en)
French (fr)
Other versions
CA2882437A1 (en
Inventor
Sylvie Laquerre
Peter F. Lebowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2882437(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2882437A1 publication Critical patent/CA2882437A1/en
Application granted granted Critical
Publication of CA2882437C publication Critical patent/CA2882437C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2882437A 2012-09-04 2013-08-30 Method of adjuvant cancer treatment Active CA2882437C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261696375P 2012-09-04 2012-09-04
US61/696,375 2012-09-04
PCT/US2013/057432 WO2014039375A1 (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Publications (2)

Publication Number Publication Date
CA2882437A1 CA2882437A1 (en) 2014-03-13
CA2882437C true CA2882437C (en) 2021-03-02

Family

ID=50237545

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2882437A Active CA2882437C (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Country Status (20)

Country Link
US (6) US20150216868A1 (enExample)
EP (2) EP2892535B1 (enExample)
JP (3) JP2015527374A (enExample)
KR (1) KR102134585B1 (enExample)
CN (2) CN104582706A (enExample)
AU (2) AU2013313050A1 (enExample)
BR (1) BR112015004578A2 (enExample)
CA (1) CA2882437C (enExample)
CY (1) CY1124812T1 (enExample)
DK (1) DK2892535T3 (enExample)
ES (1) ES2900825T3 (enExample)
HR (1) HRP20211817T1 (enExample)
HU (1) HUE056646T2 (enExample)
IN (1) IN2015KN00449A (enExample)
LT (1) LT2892535T (enExample)
PL (1) PL2892535T3 (enExample)
PT (1) PT2892535T (enExample)
RU (1) RU2640180C2 (enExample)
SI (1) SI2892535T1 (enExample)
WO (1) WO2014039375A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013313050A1 (en) 2012-09-04 2015-03-26 Novartis Ag Method of adjuvant cancer treatment
EP3378952B1 (en) 2013-12-28 2020-02-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
WO2018051306A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
KR20240032157A (ko) * 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
US11890286B2 (en) * 2018-04-17 2024-02-06 The University Of Chicago Methods and compositions for treating cancer
CN109106893B (zh) * 2018-11-12 2021-04-20 上海市中西医结合医院 一种调节肠道屏障功能的中药复方制剂及其制备方法
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
JP7769388B2 (ja) * 2019-12-12 2025-11-13 ティン セラピューティクス，インコーポレイテッド 聴覚損失の予防及び治療のための組成物及び方法
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4163738B2 (ja) * 2004-06-11 2008-10-08 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
NZ595313A (en) * 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DK3560498T3 (da) * 2009-10-16 2022-11-14 Novartis Ag Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
AU2013313050A1 (en) 2012-09-04 2015-03-26 Novartis Ag Method of adjuvant cancer treatment

Also Published As

Publication number Publication date
IN2015KN00449A (enExample) 2015-07-17
LT2892535T (lt) 2021-12-10
RU2015105821A (ru) 2016-10-20
JP6684941B2 (ja) 2020-04-22
SI2892535T1 (sl) 2022-01-31
BR112015004578A2 (pt) 2017-07-04
HRP20211817T1 (hr) 2022-03-04
CN107308164A (zh) 2017-11-03
CN104582706A (zh) 2015-04-29
HUE056646T2 (hu) 2022-02-28
JP2018058859A (ja) 2018-04-12
EP2892535A1 (en) 2015-07-15
RU2640180C2 (ru) 2017-12-26
KR102134585B1 (ko) 2020-07-17
US20200054641A1 (en) 2020-02-20
JP6511117B2 (ja) 2019-05-15
EP2892535B1 (en) 2021-09-22
AU2016244279B2 (en) 2018-01-04
EP2892535A4 (en) 2016-04-13
US10869869B2 (en) 2020-12-22
US20210060021A1 (en) 2021-03-04
PL2892535T3 (pl) 2022-01-31
EP3981408A1 (en) 2022-04-13
CA2882437A1 (en) 2014-03-13
CY1124812T1 (el) 2022-11-25
ES2900825T3 (es) 2022-03-18
AU2013313050A1 (en) 2015-03-26
KR20150047619A (ko) 2015-05-04
US20170202842A1 (en) 2017-07-20
US20230330091A1 (en) 2023-10-19
WO2014039375A1 (en) 2014-03-13
AU2016244279A1 (en) 2016-11-03
HK1206642A1 (en) 2016-01-15
JP2015527374A (ja) 2015-09-17
JP2019142899A (ja) 2019-08-29
US20180338979A1 (en) 2018-11-29
DK2892535T3 (da) 2022-01-03
US20150216868A1 (en) 2015-08-06
PT2892535T (pt) 2021-12-15

Similar Documents

Publication Publication Date Title
US10869869B2 (en) Method of adjuvant cancer treatment
US8741903B2 (en) Organic compound for use in the treatment of hepatocellular cancer (HCC)
USRE50319E1 (en) Compounds and methods for treating cancer
TW201217361A (en) Method of treating abnormal cell growth
AU2022400308B2 (en) Cdk4 inhibitor for the treatment of cancer
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
JP7278405B2 (ja) 小細胞肺がんの治療におけるキアウラニブの使用
HK40070843A (en) Dabrafenib and trametinib in a method of adjuvant cancer treatment
US20210205272A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
US20220073642A1 (en) Methods of using surufatinib in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors
HK1206642B (en) Method of adjuvant cancer treatment
RU2728932C2 (ru) Терапевтическое средство для лечения рака желчевыводящих путей
CN118354772A (zh) 治疗头颈癌的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180813

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250722